摘要:
The present invention relates to methods for weight management that utilize modified-release dosage forms comprising (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts and crystalline forms thereof. The present invention further relates to (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts, crystalline forms thereof and modified-release dosage forms comprising them.
摘要:
The present invention relates to certain compositions of a 5-HT2A serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improving sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like. The compositions disclosed herein are further useful for treating platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders and progressive multifocal leukoencephalopathy and the like.
摘要翻译:本发明涉及5-HT2A 5-羟色胺受体调节剂的某些组合物及其制备方法。 本文公开的组合物可用于增加慢波睡眠,改善睡眠巩固,改善睡眠维持和改善睡眠质量,以及用于治疗失眠和相关的睡眠障碍,睡眠障碍,异睡眠和非恢复性睡眠等。 本文公开的组合物还可用于治疗血小板聚集,冠状动脉疾病,心肌梗塞,短暂性脑缺血发作,心绞痛,中风,心房颤动,血栓形成,哮喘或其症状,其激动或症状,行为障碍,药物诱导的精神病,兴奋性 精神病,Gilles de la Tourette综合征,躁狂症,有机或NOS精神病,精神病,精神病,急性精神分裂症,慢性精神分裂症,精神分裂症精神分裂症和相关疾病,糖尿病相关疾病和进行性多灶性脑白质病等。
摘要:
An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which allows for a one-time dosage injection.
摘要:
An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which allows for a one-time dosage injection.
摘要:
A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.
摘要:
An improved weight and growth stimulant for domesticated animals such as cattle, pigs and sheep is comprised of an anabolic agent that is subcutaneously administered in the form of a dual release implant formulation. Increased gains are particularly improved when zeranol is administered in an immediate-release and controlled-release formulation which allows for a one-time dosage injection.
摘要:
A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.
摘要:
The present invention relates to certain compositions of a 5-HT2A serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improving sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like. The compositions disclosed herein are further useful for treating platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders and progressive multifocal leukoencephalopathy and the like.
摘要翻译:本发明涉及5-HT2A 5-羟色胺受体调节剂的某些组合物及其制备方法。 本文公开的组合物可用于增加慢波睡眠,改善睡眠巩固,改善睡眠维持和改善睡眠质量,以及用于治疗失眠和相关的睡眠障碍,睡眠障碍,异睡眠和非恢复性睡眠等。 本文公开的组合物还可用于治疗血小板聚集,冠状动脉疾病,心肌梗塞,短暂性脑缺血发作,心绞痛,中风,心房颤动,血栓形成,哮喘或其症状,其激动或症状,行为障碍,药物诱导的精神病,兴奋性 精神病,Gilles de la Tourette综合征,躁狂症,有机或NOS精神病,精神病,精神病,急性精神分裂症,慢性精神分裂症,精神分裂症精神分裂症和相关疾病,糖尿病相关疾病和进行性多灶性脑白质病等。
摘要:
This invention relates to the formulation of oral liquid products of quinolones or derivatives thereof using ion exchange resins, such as methacrylic acid polymer crosslinked with divinylbenzene, as the carrier, thereby eliminating the extreme bitterness of the quinolones oral liquid formulation.